Phase 3 Clinical Trials With Primary Completion Dates in September 2024
This is a list of Phase 3 trials with primary completion dates in September 2024 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| CSPCY | CSPC Pharmaceutical Group Limited | 2024-09-01 | Phase 3 | NCT05753865 | A Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Compared to Paclitaxel for Injection (Albumin-bound) |
| GLPG | Galapagos NV | 2024-09-01 | Phase 3 | NCT05785611 | A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis |
| HUMA | Humacyte, Inc. | 2024-09-01 | Phase 3 | NCT03183245 | Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis |
| IMUX | Immunic, Inc. | 2024-09-01 | Phase 3 | NCT05134441 | Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis |
| KSPHF | Kissei Pharmaceutical Co., Ltd. | 2024-09-01 | Phase 3 | NCT05445167 | A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia and Pain |
| MIRM | Mirum Pharmaceuticals, Inc. | 2024-09-01 | Phase 3 | NCT04185363 | An Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC) |
| MNKD | MannKind Corporation | 2024-09-01 | Phase 3 | NCT04974528 | Afrezza® INHALE-1 Study in Pediatrics |
| OTLK | Outlook Therapeutics, Inc. | 2024-09-01 | Phase 3 | NCT06190093 | A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) |
| PRAX | Praxis Precision Medicines, Inc. | 2024-09-01 | Phase 3 | NCT06087276 | Essential 3 - Decentralized, Phase 3 Study Evaluating the Safety and Efficacy of Ulixacaltamide in Essential Tremor (ET) |